Fri, October 28, 2011
Thu, October 27, 2011
Wed, October 26, 2011
Tue, October 25, 2011
Mon, October 24, 2011
[ Mon, Oct 24th 2011 ] - Market Wire
Cigna to Acquire HealthSpring
Sat, October 22, 2011
Fri, October 21, 2011
Thu, October 20, 2011
Wed, October 19, 2011
Tue, October 18, 2011
Mon, October 17, 2011
Sun, October 16, 2011
Sat, October 15, 2011
Fri, October 14, 2011
Thu, October 13, 2011

Federman &;; Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against K-V Pharmaceutical Comp


//health-fitness.news-articles.net/content/2011/ .. -been-filed-against-k-v-pharmaceutical-comp.html
Published in Health and Fitness on Friday, October 21st 2011 at 11:42 GMT by Market Wire   Print publication without navigation


October 21, 2011 14:30 ET

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against K-V Pharmaceutical Company (NYSE: KV-A) (NYSE: KV-B)

OKLAHOMA CITY, OK--(Marketwire - Oct 21, 2011) - On October 19, 2011, a class action lawsuit was filed in the United States District Court for the Eastern District of Missouri against K-V Pharmaceutical Company (NYSE: [ KV-A ]) (NYSE: [ KV-B ]). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material misrepresentations to the market which had the effect of artificially inflating the market price, and the manufacture and distribution of unapproved drugs through its two (2) subsidiaries, Ther-Rx and ETHEX. The class period is from February 14, 2011 through April 4, 2011.

Plaintiff seeks to recover damages on behalf of the Class. If you are a member of the Class as described above, you may move the Court no later than Monday, December 19, 2011, to serve as a lead plaintiff for the Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, participate in this or any other lawsuit, or have any questions or concerns regarding this notice, or preservation of your rights, please contact:



Publication Contributing Sources